A Diabetes Outcomes Progression Trial

ADOPT Conference Abstracts

• Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial) [43rd Annual Meeting of the European Association for the Study of Diabetes]

  1 January 2007

• Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain [43rd Annual Meeting of the European Association for the Study of Diabetes]

  1 January 2007

• Determinants of monotherapy failure in ADOPT (A Diabetes Outcome Progression Trial) [43rd Annual Meeting of the European Association for the Study of Diabetes]

  1 January 2007

• ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes [43rd Annual Meeting of the European Association for the Study of Diabetes]

  1 January 2007

• Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in recently diagnosed, drug-naive type 2 diabetes: the ADOPT study cohort [41st Annual Meeting of the European Association for the Study of Diabetes]

  1 January 2005

• BMI and ratio of triglycerides to HDL are most predictive of insulin resistance in a drug naive population with type 2 diabetes [41st Annual Meeting of the European Association for the Study of Diabetes]

  1 January 2005

• Hepatic enzymes are associated with insulin resistance and impaired fibrinolysis in drug naïve, recently diagnosed type 2 diabetes subjects [65th Scientific Sessions of the American Diabetes Association]

  1 January 2005

• Obesity is a major determinant of the association of C-reactive protein levels with the number of metabolic syndrome components in type 2 diabetes [65th Scientific Sessions of the American Diabetes Association]

  1 January 2005

• Estimations of the clinical benefit of optimal blood glucose, blood pressure and lipid control in type 2 diabetic patients with the metabolic syndrome [18th International Diabetes Federation Congress]

  1 January 2003

• Differences in the prevalence of the metabolic syndrome between ethnic groups in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study [18th International Diabetes Federation Congress]

  1 January 2003

• Symptoms and health status in a recently-diagnosed type 2 diabetic population: the ADOPT study [18th International Diabetes Federation Congress]

  1 January 2003

• Are different clinical practice guidelines associated with regional differences in diabetes care? [18th International Diabetes Federation Congress]

  1 January 2003

• Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort. [18th International Diabetes Federation Congress]

  1 January 2003

• Prevalence of microalbuminuria in recently diagnosed type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study [18th International Diabetes Federation Congress]

  1 January 2003

• Lack of concordance of WHO and NCEP criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort [18th International Diabetes Federation Congress]

  1 January 2003

• Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study [18th International Diabetes Federation Congress]

  1 January 2003

• Ethnic differences in the prevalence of the metabolic syndrome in recently diagnosed type 2 diabetes in the North American cohort of the ADOPT study [63rd Scientific Sessions of the American Diabetes Association]

  1 January 2003

• Lack of concordance of NCEP and WHO criteria for the diagnosis of the metabolic syndrome in recently diagnosed diabetes in North America and Europe in the ADOPT study cohort [63rd Scientific Sessions of the American Diabetes Association]

  1 January 2003

• Prevalence of microalbuminuria and its relationship to non-traditional risk factors in recently diagnosed type 2 diabetes mellitus: observations from the ADOPT study [63rd Scientific Sessions of the American Diabetes Association]

  1 January 2003

• Prevalence and clinical significance of glutamic acid decarboxylase (GAD) antibodies in recently diagnosed type 2 diabetes in the ADOPT study cohort [63rd Scientific Sessions of the American Diabetes Association]

  1 January 2003